Vir, GSK’s COVID-19 antibody treatment works against omicron in a lab study, and WHO no longer recommends convalescent plasma

By: MarketWatch

December 07, 2021 at 10:31 AM EST

Vir Biotechnology and GlaxoSmithKline’s COVID-19 antibody treatment worked against omicron in a laboratory study.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Vir, GSK’s COVID-19 antibody treatment works against omicron in a lab study, and WHO no longer recommends convalescent plasma

Sections

Services

Big Spring, TX (79721)

Today

Tonight

Vir, GSK’s COVID-19 antibody treatment works against omicron in a lab study, and WHO no longer recommends convalescent plasma

Sections

Services